- Home
- INCR vs OKUR Comparison
INCR vs OKUR Comparison
Compare INCR & OKUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- OKUR
- Stock Information
- Founded
- INCR 1994
- OKUR 2011
- Country
- INCR Israel
- OKUR United States
- Employees
- INCR N/A
- OKUR N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- OKUR
- Sector
- INCR Health Care
- OKUR
- Exchange
- INCR Nasdaq
- OKUR NYSE
- Market Cap
- INCR 76.7M
- OKUR 77.2M
- IPO Year
- INCR N/A
- OKUR N/A
- Fundamental
- Price
- INCR $1.70
- OKUR $5.79
- Analyst Decision
- INCR
- OKUR Strong Buy
- Analyst Count
- INCR 0
- OKUR 3
- Target Price
- INCR N/A
- OKUR $36.00
- AVG Volume (30 Days)
- INCR 43.9K
- OKUR 176.8K
- Earning Date
- INCR 02-15-2025
- OKUR 02-14-2025
- Dividend Yield
- INCR N/A
- OKUR N/A
- EPS Growth
- INCR N/A
- OKUR N/A
- EPS
- INCR N/A
- OKUR N/A
- Revenue
- INCR $72,420,918.00
- OKUR N/A
- Revenue This Year
- INCR N/A
- OKUR N/A
- Revenue Next Year
- INCR $39.30
- OKUR N/A
- P/E Ratio
- INCR N/A
- OKUR N/A
- Revenue Growth
- INCR N/A
- OKUR N/A
- 52 Week Low
- INCR $1.17
- OKUR $5.75
- 52 Week High
- INCR $3.72
- OKUR $20.00
- Technical
- Relative Strength Index (RSI)
- INCR 57.80
- OKUR N/A
- Support Level
- INCR $1.63
- OKUR N/A
- Resistance Level
- INCR $1.75
- OKUR N/A
- Average True Range (ATR)
- INCR 0.07
- OKUR 0.00
- MACD
- INCR 0.01
- OKUR 0.00
- Stochastic Oscillator
- INCR 64.57
- OKUR 0.00
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.